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Abstract
Background: During the female reproductive cycle, follicular development and corpus luteum
formation crucially depend on the fast generation of new blood vessels. The importance of
granulosa cells and follicular fluid in controlling this angiogenesis is still not completely understood.
Vascular endothelial growth factor (VEGF) produced by granulosa cells and secreted into the
follicular fluid plays an essential role in this process. On the other hand, soluble VEGF receptor-1
(sFlt-1) produced by endothelial cells acts as a negative modulator for the bioavailability of VEGF.
However, the regulation of sFlt-1 production remains to be determined.
Methods: We analyzed the influence of human follicular fluid obtained from FSH-stimulated
women as well as of human granulosa cell conditioned medium on sFlt-1 production in and release
from human umbilical vein endothelial cells (HUVEC) in vitro. Soluble Flt-1 gene expression was
determined by RT-PCR analysis, amount of sFlt-1-protein was quantified by Sandwich-ELISA.
Results: Human follicular fluid as well as granulosa cell-conditioned medium significantly inhibit the
production of sFlt-1 by endothelial cells on a posttranscriptional level. Treatment of cultured
granulosa cells with either hCG or FSH had not impact on the production of sFlt-1 inhibiting
factors. We further present data suggesting that this as yet unknown sFlt-1 regulating factor
secreted by granulosa cells is not heat-sensitive, not steroidal, and it is of low molecular mass (<
1000 Da).
Conclusion: We provide strong support that follicular fluid and granulosa cells control VEGF
availability by down regulation of the soluble antagonist sFlt-1 leading to an increase of free,
bioactive VEGF for maximal induction of vessel growth in the ovary.
Background
Angiogenesis is a rare process in normal adult organs pre-
dominantly occurring during wound healing and tumor
growth. However, under physiological conditions it plays
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an important role in the female reproductive tract with
regard to follicular development, corpus luteum forma-
tion, and uterine endometrial proliferation during the
menstrual cycle [1,2]. Here, the cyclic corpus luteum of
the ovary is the organ with the strongest physiological
angiogenesis [3,4]. Defects in ovarian angiogenesis may
contribute to a variety of disorders including anovulation
and infertility, pregnancy loss, ovarian hyperstimulation
syndrome, and ovarian neoplasms [5-7].
During follicular growth, angiogenesis is restricted to the
theca cell layer. After ovulation, however, massive angio-
genesis occurs and new blood vessels penetrate the base-
ment membrane of the follicle invading the growing
corpus luteum [8]. The establishment of such a complex
capillary network requires precise timing. Angiogenesis
depends on a balance between positive and negative
endothelial regulators [9]. Among the many endothelial
regulators, vascular endothelial growth factor (VEGF) has
been characterized as the most potent promoter of angio-
genesis. This key regulator acts specifically on endothelial
cells by stimulating cell growth, differentiation, migration
and permeability [10,11]. VEGF, especially the isoforms
VEGF-A121 and VEGF-A165, are produced by human gran-
ulosa cells [5,12-15], and VEGF-dependent angiogenesis
is essential for corpus luteum development [16]. VEGF
expression in granulosa cells can be increased by gonado-
tropins (FSH, hCG) [17,18]. The biological activity of
VEGF is mediated by two tyrosine kinase family receptors
that are located on endothelial cells (VEGFR-1 = flt-1,
VEGFR-2 = KDR) [19]. Binding of VEGF to either of the
receptors induces autophosphorylation and signal trans-
duction. Besides these transmembrane receptors, a solu-
ble receptor (sFlt-1) is generated in endothelial cells by
differential splicing of the VEGFR-1 mRNA [20,21]. Solu-
ble Flt-1 retains full VEGF binding potency and acts as an
inhibitor of VEGF bioactivity by sequestering VEGF, thus
reducing the ligand binding to transmembrane and sig-
nalling receptors [22,23]. It plays a pivotal role in the gen-
eration of vascular diseases like pre-eclampsia or intra-
uterine growth retardation [24], and could be linked to
the ovarian response to stimulation protocols [25].
The regulation of sFlt-1 production in endothelial cells
remains to be determined. In the ovary, it could be dem-
onstrated in high amounts in follicular fluid aspirated
during IVF oocyte retrieval. The function of the avascular
granulosa cell layer in controlling angiogenesis in the
vicinity of developing follicles is still a matter of discus-
sion. In the present study we analyzed the influence of
human follicular fluid as well as of human granulosa cell
conditioned medium on Flt-1 production and release by
human endothelial cells.
Materials and methods
Follicular fluid
Follicular fluid was obtained by follicular aspiration from
15 FSH-treated women (34.6 ± 5.6 years) undergoing
oocyte retrieval for in vitro fertilization (IVF/ICSI) at the
Department of Gynecological Endocrinology at the Uni-
versity Hospital Aachen, Germany. The experimental
design was approved by the local ethical committee of the
University Hospital Aachen (# EK 2008). Written
informed consent was obtained from patients individu-
ally. IVF/ICSI was performed due to tubal occlusion (7),
andrological (6) or idiopathic (2) reasons. Ovarian stim-
ulation and oocyte retrieval were performed as described
previously [26]. After removal of oocytes, follicular fluids
of individual patients were pooled, and centrifuged at 500
g for 5 min. Supernatants were frozen at -20°C until fur-
ther processing.
Follicular fluid was partially purified by using two succes-
sive ultrafiltration units with different molecular weight
cut offs (MWCOs). To prevent clogging of filters, a
100000 Da ultra-filter (Millipore GmbH, Eschborn, Ger-
many) was used as a pre-filter. The first flow through was
consecutively treated with a 1000 Da filter unit (Pall Life
Sciences, Ann Arbor, MI). Depending on the follicular
fluid's viscosity centrifugation steps were carried out both
times for 4–6 hours at 4400 g and 4°C. The final flow
through was then incubated either directly with HUVECs
or treated further as follows: heating for 10 minutes at
96°C, or dialysis with 100 Da MWCO membranes (Spec-
trum Laboratories Inc., Rancho Dominguez, CA) equili-
brated against two changes of a two hundredfold volume
PBS over a 6 hour period at 4°C. In another experiment
the partially purified follicular fluid was stirred with dex-
tran-coated charcoal (Sigma-Aldrich Chemie GmbH,
Taufkirchen, Germany) at a concentration of 10 mg/ml
for 30 minutes at room temperature to absorb free ster-
oids and fatty acids. Any precipitated material or charcoal
was removed by centrifugation for 5 minutes at 13 600 g
and 4°C.
Granulosa cell culture
Human granulosa cells were obtained by follicular aspira-
tion from FSH-treated women as described before [26].
Cells were plated at a density of 5 × 105 cells/well in 6-well
dishes and cultured in M199 Earle's Medium supple-
mented with 10% FCS, 2 mM L-glutamine, and 1% Pen/
Strep (all Biochrom, Berlin, Germany) at 37°C in 95% air-
5% CO2 humidified environment. In one experimental
group, medium was additionally supplemented with FSH
(Gonal F, Serono, 100 ng/ml), in another experimental
group with hCG (Pregnesin, Serono, 1 IU / ml). Cell cul-
ture medium was changed after 24 hours and was then
harvested after 4 days of culturing and stored at -20°C
until further use.Reproductive Biology and Endocrinology 2005, 3:57 http://www.rbej.com/content/3/1/57
Page 3 of 7
(page number not for citation purposes)
Endothelial cell culture
Human umbilical vein endothelial cells (HUVEC) were
isolated from umbilical cords and cultured as described
previously [26]. For each experiment, HUVECs of 3–5
umbilical veins were pooled and seeded in 6- or 12-well
plates. At confluence after two days of culturing cells were
incubated either with culture medium alone, with culture
medium containing 30% follicular fluid (in those experi-
ments with constant concentration of follicular fluid) or
with 30% GC-conditioned medium, respectively. After up
to 4 days of incubation at 37°C culture medium was col-
lected, centrifuged and supernatant was frozen at -20°C,
endothelial cells were harvested and frozen at -20°C until
RNA-preparation. For each experimental design HUVECs
were separately incubated with follicular fluid or GC-con-
ditioned medium, respectively, of at least 5 different
patients.
Proliferation studies
Human umbilical vein endothelial cells were seeded into
24-well-plates with a density of 50000 cells per well. Cells
were incubated with culture medium containing 30% fol-
licular fluid for up to 4 days or with culture medium alone
as a control. Growth rates were determined in nine exper-
iments with follicular fluid of nine different patients using
an electronic Coulter counter (CASY 1, Schärfe System,
Reutlingen, Germany). Each probe has been measured
twice.
Quantification of sFlt-1 protein
Total sFlt-1 concentration in HUVEC supernatant was
quantified with a specific enzyme-linked immunosorbent
assay (ELISA) (RELIATech, Braunschweig, Germany [22]
and BMS268, Bender MedSystems GmbH, Vienna, Aus-
tria). Intra- and inter-assay co-efficiencies were CV<10%
and CV<20%, respectively. Soluble Flt-1 ELISA analyses
were performed in duplicate for each probe.
RT-PCR
Isolation of total RNA from eutopic endometrial tissues as
well as from endometrial tissue grown in nude mice was
performed using the RNeasy Minikit® (Qiagen, Hilden,
Germany) according to the manufactures instructions.
The concentration of RNA was determined spectrophoto-
metrically and the RNA was stored at -80°C until use.
Reverse transcription of RNA from HUVECs treated with
follicular fluid or granulosa cell conditioned medium was
carried out as described previously [26]. Briefly, two
micrograms of total RNA were digested with DNase I (Inv-
itrogen, Karlsruhe, Germany) and transcribed into cDNA
by reverse transcription with M-MLV Reverse Tran-
scriptase (Invitrogen, Karlsruhe, Germany) using an oligo
(dT)16 primer in a total volume of 50 µl. Reverse transcrip-
tion was performed for 60 min at 37°C in a thermocycler
(Biometra, Göttingen, Germany) followed by 10 min at
90°C. 4 µl of the RT-reaction were used for PCR experi-
ments. The following primers were used: sFlt-1 forward 5'-
GCACCTTGGTTGTGGCTGAC-3'; sFlt-1 reverse 5'-AAT-
GTTTTACATTACTTTGTGTGG-3' (product size 510 bp), β-
actin forward 5'-ACCAACTGGGACGACATGGAGAAAA-
Proliferation of HUVECs incubated with culture medium  containing 30% follicular fluid (+FF) or incubated with culture  medium alone (control) for up to 4 days Figure 1
Proliferation of HUVECs incubated with culture medium 
containing 30% follicular fluid (+FF) or incubated with culture 
medium alone (control) for up to 4 days. From day 3 
onwards a significant increase in cell number can be observed 
for those endothelial cells treated with follicular fluid com-
pared to controls. * = p < 0.05.
Amount of sFlt-1 in the culture supernatant of HUVECs  treated with medium only (grey bars) or with medium con- taining 30% human follicular fluid (FF, black bars) for up to 3  days Figure 2
Amount of sFlt-1 in the culture supernatant of HUVECs 
treated with medium only (grey bars) or with medium con-
taining 30% human follicular fluid (FF, black bars) for up to 3 
days. From day 2 onwards a significant increase in sFlt-1 con-
tent can be observed for those endothelial cells treated with 
medium only but not for those incubated with medium con-
taining follicular fluid. * = p < 0.05.Reproductive Biology and Endocrinology 2005, 3:57 http://www.rbej.com/content/3/1/57
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3',  β-actin reverse 5'-TACGGCCAGAGGCGTACAGGGA-
TAG-3' (product size 214 bp). Amplifications were run in
50 µl volume using BioTherm Taq polymerase (Genecraft,
Muenster, Germany) for 35 amplification cycles of 30 sec
denaturation at 94°C, 45 sec annealing at 62°C and 30
sec elongation at 72°C. The PCR amplification was fol-
lowed by a 10 minute final extension at 72°C. The condi-
tions were chosen so that the sflt-1 cDNA as well as the
control β-actin cDNA were in the exponential phase of
amplification and did not reach a plateau at the end of the
amplification protocol. The generated PCR amplification
products were electrophoresed on a 2% agarose gel and
detected by ethidiumbromide staining. PCR products
were normalized to β-actin by densitometric analysis
using a Gel imager (Intas, Goettingen, Germany) and
were relatively quantified (Gelscan Professional V4.0).
Statistical analysis
Statistical analysis was performed using the non-paramet-
ric Mann-Whitney test. The level of significance was set at
p < 0.05.
Results
Regulation of endothelial cell proliferation and sFlt-1 
secretion by follicular fluid
Incubation of HUVECs with culture medium containing
30% follicular fluid led to a significant increase in cell
number compared to controls on day 3 and 4 of culturing
(Fig. 1). Analyzing secretion of sFlt-1 by endothelial cells,
HUVECs secreted 14.63 ± 1.36 ng sFlt-1 per ml into the
culture medium during 24 hours of monolayer culture
(Fig. 2). After 3 days of culture the amount of secreted sFlt-
1 accumulated to 37.2 ± 5.2 ng/ml. This increase in sFlt-1
-1 was inhibited by the presence of 30% follicular fluid in
the culture medium (Fig. 2). The inhibition of sFlt-1 pro-
duction was proven to show a dose-effect as it was
dependent on the concentration of follicular fluid in the
culture medium. The amount of sFlt-1 decreased with
increasing concentration of follicular fluid, showing a sig-
nificant inhibition of sFlt-1 production at a concentration
of 30% (Fig. 3).
To exclude an unspecific role of FCS on sFlt-1 production
in HUVECs, culture medium containing FCS had been
either untreated, heat inactivated or FCS was omitted.
There was no measurable effect of either of these controls
on sFlt-1 production of endothelial cells (Fig. 4). To ana-
lyze the follicular fluid in regard to factors possibly
responsible for sFlt-1 regulation, follicular fluid has been
partially purified by ultrafiltration. The resulting flow
through containing only molecules smaller than 1000
Dalton still significantly inhibited sFlt-1 secretion by
endothelial cells. Moreover, this effect could not be pre-
vented by exposure of the flow through to heat or charcoal
treatment (Fig. 4).
Amount of sFlt-1 in the culture supernatant of HUVECs after  4 days of incubation with medium containing different con- centrations of human follicular fluid Figure 3
Amount of sFlt-1 in the culture supernatant of HUVECs after 
4 days of incubation with medium containing different con-
centrations of human follicular fluid. Amount of sFlt-1 
decreases with increasing concentrations of follicular fluid 
showing a significant inhibition of sFlt-1 production at a con-
centration of 30%. * = p < 0.05.
Quantification of sFlt-1 in endothelial cell culture supernatant Figure 4
Quantification of sFlt-1 in endothelial cell culture superna-
tant. Neither heat inactivation of culture medium containing 
FCS (C2) nor absence of FCS (C3) has a measurable effect 
on sFlt-1 production of endothelial cells compared to incuba-
tion with untreated control medium containing FCS (C1). 
The significant inhibitory effect of untreated human follicular 
fluid (FF) on sFlt-1 production is maintained after ultra filtra-
tion leaving only molecules smaller than 1000 Dalton. This 
inhibition is not prevented neither by heat inactivation nor by 
charcoal treatment of the follicular fluid-flow through. All fol-
licular fluids have been added to the culture medium at a 
concentration of 30%. * = p < 0.05Reproductive Biology and Endocrinology 2005, 3:57 http://www.rbej.com/content/3/1/57
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Transcription of sFlt-1 is not regulated by follicular fluid
RT-PCR analysis of HUVECs incubated with medium con-
taining 30% follicular fluid revealed a slight but not
significant decrease in sFlt-1 expression compared to
endothelial cells treated with medium only (Fig. 5), point-
ing to a presumable posttranscriptional regulatory mech-
anism of this soluble receptor by follicular fluid.
Regulation of sFlt-1 secretion by granulosa cell-
conditioned medium
This inhibition of sFlt-1 production by endothelial cells
was also obtained by incubation of HUVECs with granu-
losa cell-conditioned medium. At the concentration of
30% granulosa cell-conditioned medium a significant
inhibition of sFlt-1 production could be observed after 4
days of culturing (Fig. 6). This inhibition was not
influenced by incubation of the granulosa cell culture
either with FCS or hCG. In general, however, treatment
with granulosa cell-conditioned medium resulted in a
lesser inhibition of sFlt-1 production compared to the
inhibition by corresponding follicular fluid of the same
patients (Fig. 6).
Discussion
In the present study we demonstrate that human follicular
fluid significantly increases proliferation and inhibits the
production of the VEGF antagonist sFlt-1 in endothelial
cells. It is proven that granulosa cells produce large
amounts of VEGF which plays the key role in corpus
luteum angiogenesis in vivo [16]. The biological activity
of VEGF depends on the availability of this protein to its
transmembrane receptors Flt-1 (VEGFR-1) and KDR
(VEGFR-2). Soluble Flt-1 is secreted by endothelial cells
[20] and acts as a receptor antagonist by sequestering free
VEGF, thus repressing angiogenesis mediated by VEGF
[22,23]. Soluble Flt-1 may modulate VEGF activity in
physiological as well as in patho-physiological angiogen-
esis in the female reproductive tract. It is secreted by the
placenta and released into the maternal circulation during
pregnancy [27], and it could be shown that preeclampsia
is associated with increased levels of sFlt-1 [24,28-30]. In
addition, it could be shown that excess in sFlt-1 goes in
parallel with poor response to gonadotropins in stimula-
tion protocols due to the decreased availability of bioac-
tive VEGF [25]. An influence of sFlt-1 on physiological
angiogenesis in the ovary was shown by Ferrara and co-
workers [16] who reported that treatment with truncated
sFlt-1 receptors resulted in complete suppression of cor-
pus luteum angiogenesis in a rat model.
The role of the avascular granulosa cell layer in controlling
angiogenesis in the developing follicles is still not clari-
fied. It has been shown before that human follicular fluid
contains angiogenic factors such as basic fibroblast
growth factors [31], angiogenin [32] and VEGF [33] and
RT-PCR of mRNA of HUVECs incubated with medium only  (C) or with medium containing 30% follicular fluid (+FF) Figure 5
RT-PCR of mRNA of HUVECs incubated with medium only 
(C) or with medium containing 30% follicular fluid (+FF). 
Densitometric evaluation revealed no significant difference in 
mRNA-expression of sFlt-1 between these two experimental 
groups at p < 0.05.
Amount of sFlt-1 in the culture supernatant of HUVECs incu- bated for 4 days with medium containing 30% granulosa cell  (GC)-conditioned medium Figure 6
Amount of sFlt-1 in the culture supernatant of HUVECs incu-
bated for 4 days with medium containing 30% granulosa cell 
(GC)-conditioned medium. Addition of GC-conditioned 
medium leads to a significant inhibition of sFlt-1 production 
of HUVECs (*). Treatment of granulosa cells with FCS or 
hCG during conditioning of medium has no influence on this 
inhibition. Incubation with follicular fluid (FF) of the same 
patients leads to a significant reduced production of sFlt-1 
compared to controls as well as to treatment with GC-con-
ditioned medium (**). p < 0.05.Reproductive Biology and Endocrinology 2005, 3:57 http://www.rbej.com/content/3/1/57
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that follicular fluid has the capacity to induce angiogen-
esis [34]. As demonstrated in the present study, the inhi-
bition of sFlt-1 by factors secreted by granulosa cells, thus
increasing the amount of free, bioactive VEGF, may repre-
sent another regulatory level involved in the angiogenic
cascade. Though it is known that soluble receptor protein
is generated by alternative splicing of Flt-1 pre-mRNA [35]
and exogenous sFlt-1 can dramatically inhibit biological
actions of VEGF, there is still little information about
physiological functions of sFlt-1 or the mechanisms con-
trolling its biosynthesis. We demonstrated here that fac-
tors secreted by granulosa cells and which are contained
in follicular fluid inhibit sFlt-1 production, and that this
regulation mainly occurs on a posttranscriptional level.
This is concordant with our former microarray analyses
showing that sFlt-1 mRNA was not amongst the genes sig-
nificantly regulated by follicular fluid in endothelial cells
[26]. A post-transcriptional control of sFlt-1 expression
could also be demonstrated by Huckle and Roche [36]
using cleavage-polyadenylation mutants of the mouse Flt-
1 intron 13. Thus, an opportunity exists for granulosa cells
to regulate sFlt-1 protein expression at a widely constant
rate of sFlt-1 gene transcription. However, in cyclic human
endometrium regulation of sFlt-1 could be demonstrated
on a transcriptional level [37] pointing to different regula-
tory pathways in different organs. The weaker effect of
granulosa cell conditioned medium on inhibition of sFlt-
1 compared to follicular fluid could be due to a lower
concentration of the inhibitory factor in the granulosa cell
conditioned medium since this medium was harvested
already after 4 days. Though FSH as well as LH / hCG
application are able to increase VEGF expression in
human granulosa cells [17,18], treatment of cultured
luteal granulosa cells either with hCG or FSH had no effect
on the inhibition of sFlt-1 secretion. Redmer and co-work-
ers [38] showed that luteal cells secrete a non-steroidal
factor which stimulates migration of endothelial cells and
that pre-treatment of the luteal cultures with hCG or FSH
had no effect on the endothelial cell migration stimulat-
ing activity of luteal cell conditioned media. Since the
granulosa cells have been exposed to FSH in vivo, a regu-
latory effect of this hormone can not be excluded. How-
ever, depletion of FSH in vitro had no effect on the
production of this factor. The nature of the inhibitory fac-
tor(s) secreted by granulosa cells is still unknown. As
demonstrated here, the factor is of low molecular mass (<
1000 Da) and heat inactivation does not change the
inhibitory effect on sFlt-1 secretion. In addition, a steroi-
dal nature can be excluded since this effect is not be elim-
inated by charcoal treatment.
A complex cascade of events regulated on a transcriptional
as well as post-transcriptional level might contribute to
the initiation, progression, morphogenesis and regression
of blood vessels in the ovary. We have shown previously
that after the LH surge, yet before ovulation, granulosa
cells secrete factors resulting in destabilization of vessel
walls by down-regulating of fibulin-5 and elastin and up-
regulation of angiopoietin-2 [26]. In addition, granulosa
cells may improve the sprouting of new vessels by down-
regulation of the soluble antagonist sFlt-1 thus enhancing
the amount of bioactive VEGF. This suppression of sFlt-1
immediately before corpus luteum formation may act to
rapidly promote and fine tune angiogenesis in this
ephemeral organ. The release in the ovary could be one
factor which helps to explain the temporal and spatial dis-
crepancy between the high expression of VEGF in the
granulosa cells and the restriction of angiogenesis to the
thecal layer in the pre-ovulatory follicle. Disruption of this
balance between VEGF and sFlt-1 may result in a dis-
turbed physiological state or various pathological condi-
tions. Understanding the underlying molecular
mechanisms which regulate the complex angiogenic cas-
cade is a major challenge with implications for the under-
standing of blood vessel growth and regression in
reproductive biology as well as in pathological
conditions.
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